UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

ASLAN Pharmaceuticals

Clinical-stage company developing treatments for inflammatory diseases

ASLAN Pharmaceuticals logo

ASLAN Pharmaceuticals

BiotechnologySingapore

Clinical-stage company developing treatments for inflammatory diseases

Visit Website

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is a dual-listed (NASDAQ: ASLN; Taiwan Stock Exchange) clinical-stage biopharmaceutical company headquartered in Singapore, with operations in Taiwan and the United States. Founded in 2010, the company concentrates its pipeline on inflammatory diseases and oncology, with a particular strategic emphasis on conditions where patients lack effective treatment options.

The company's lead asset is farudodstat (ASLAN004), a monoclonal antibody that blocks both the IL-13 receptor alpha-1 and IL-4 receptor alpha subunits. This dual mechanism is designed to address the full spectrum of type 2 inflammation and is being evaluated in moderate-to-severe atopic dermatitis and ulcerative colitis. ASLAN Pharmaceuticals has conducted Phase 2 studies across these indications, with clinical data guiding its ongoing development strategy.

Pipeline Focus and Business Model

ASLAN Pharmaceuticals operates a capital-light model, progressing internally discovered compounds through clinical proof-of-concept before seeking regional or global partnership arrangements. The company has previously evaluated oncology assets including varlitinib, a pan-ErbB inhibitor studied in biliary tract cancer and gastric cancer, and retains scientific capabilities across both immunology and oncology drug discovery.

With its Asia-Pacific base, ASLAN is positioned to run efficient clinical programmes in markets with high patient enrolment potential, supporting faster data generation across its therapeutic areas.

Further information is available at aslanpharma.com.

Areas of Expertise

Atopic DermatitisClinical DevelopmentDrug DiscoveryImmunologyInflammatory DiseaseOncology

Services & Capabilities

Atopic DermatitisClinical DevelopmentDrug DiscoveryImmunologyInflammatory DiseaseOncology
Similar Companies

More in Biotechnology

A

AMO Pharma

AMO Pharma is building a portfolio of new medicines targeting serious and debilitating diseases, with a particular focus on rare and orphan genetic disorders. The privately held emerging biopharmaceutical company, headquartered in London, identifies and advances promising therapies for patient populations facing significant unmet need, guided by the principle that clinical development should deliver measurable value to patients at every stage of the journey. The pipeline reflects that commitment. AMO Pharma is progressing multiple candidates, including AMO-01, AMO-02, and AMO-04, across conditions that include Phelan-McDermid Syndrome, Rett Syndrome, and congenital myotonic dystrophy. The REACH-CDM pivotal clinical trial for congenital myotonic dystrophy represents a significant milestone in the company's development programme. Each indication falls within the rare or orphan disease space, where AMO Pharma's strategy is to identify assets with high potential impact and advance them through all phases of development, from early research through to potential approval. The company is led by a team of seasoned industry professionals who bring extensive experience in biomedical science, research, and asset acquisition across all phases of pharmaceutical development. This experienced leadership team combines deep scientific knowledge with commercial expertise, enabling a disciplined approach to candidate selection and clinical execution. AMO Pharma also maintains an active partnerships function, reflecting a business model that combines internal expertise with external collaboration to move treatments forward for underserved patient communities. Further information is available at amo-pharma.com.

View profile
E

Emergex

Emergex Vaccines is a UK-based clinical-stage biotechnology company developing a new class of synthetic peptide vaccines designed to stimulate cytotoxic T-lymphocyte (CTL) responses rather than the antibody-driven immunity targeted by conventional vaccines. Founded in 2015 and headquartered in Abingdon, Oxfordshire, the company was established on the premise that T-cell immunity offers broader and more durable protection against rapidly mutating viral pathogens, including pandemic influenza strains and other emerging infectious threats. Platform Technology and Pipeline The company's core platform centres on short synthetic peptide constructs derived from conserved viral protein sequences. Because these sequences change little across viral variants, the approach aims to produce vaccines with cross-strain efficacy, addressing a central limitation of seasonal influenza vaccines that must be reformulated annually. Emergex has advanced candidates targeting influenza A and dengue fever through early-phase clinical evaluation, with additional programmes directed at other flaviviruses and respiratory viruses. Development and Funding Background Emergex has received support from UK public funding bodies and private investors to progress its pipeline from pre-clinical research into Phase I clinical trials. The company operates under a largely asset-light model, collaborating with contract research organisations and academic partners to conduct clinical work. As a private company, Emergex does not carry a public stock listing. Its programmes are positioned within the broader landscape of next-generation vaccine development, addressing unmet needs in both seasonal infectious disease management and pandemic preparedness. Further information is available at emergexvaccines.com.

View profile
A

AN2 Therapeutics

Grounded in a proprietary boron chemistry platform, AN2 Therapeutics is a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics for rare, chronic, and serious infectious diseases. The company's approach centres on translating boron chemistry into candidates that address critical unmet needs across multiple therapy areas, targeting patients where existing treatment options remain inadequate. The development pipeline spans haematologic diseases, infectious diseases and oncology, with additional early-stage research programmes directed at oncology targets, bone disorders, and infectious disease. This breadth reflects the versatility of the underlying chemistry platform and the company's stated commitment to delivering high-impact medicines. AN2 Therapeutics is led by Co-Founder, President and Chief Executive Officer Eric Easom, who brings over 35 years of leadership experience in the biotechnology and pharmaceutical industry. A significant portion of that career, spanning more than two decades, has been focused on addressing unmet needs in infectious diseases, particularly those affecting the developing world. The leadership team also includes Michael R.K. (Dickon) Alley, Ph.D. as SVP Research Fellow and Head of Biology, Sanjay Chanda, Ph.D. as Chief Development Officer, Lucy O. Day as Chief Financial Officer, Josh Eizen as Chief Legal Officer and Chief Operating Officer, and Vince Hernandez as Senior Vice President of Research and Head of Chemistry. Further information is available at an2therapeutics.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy